Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · IEX Real-Time Price · USD
10.27
+0.04 (0.39%)
At close: Jul 17, 2024, 4:00 PM
10.46
+0.19 (1.85%)
After-hours: Jul 17, 2024, 7:48 PM EDT

Company Description

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases.

Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV).

The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology, Inc.
Vir Biotechnology logo
Country United States
Founded 2016
IPO Date Oct 11, 2019
Industry Biotechnology
Sector Healthcare
Employees 587
CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Contact Details

Address:
1800 Owens Street, Suite 900
San Francisco, California 94158
United States
Phone 415-906-4324
Website vir.bio

Stock Details

Ticker Symbol VIR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001706431
CUSIP Number 92764N102
ISIN Number US92764N1028
Employer ID 81-2730369
SIC Code 2836

Key Executives

Name Position
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. Chief Executive Officer and Director
Dr. Ann M. Hanly Ph.D. Executive Vice President and Chief Technology Officer
Dr. Klaus Frueh Ph.D. Co-Founder and Scientific Advisor
Dr. Lawrence Corey M.D. Co-Founder and Scientific Advisor
Dr. Louis J. Picker M.D. Co-Founder and Scientific Advisor
Sung H. Lee Executive Vice President and Chief Financial Officer
Dr. Jennifer Eileen Towne Ph.D. Executive Vice President and Chief Scientific Officer
Heather Rowe Armstrong Vice President of Investor Relations
Vanina De Verneuil J.D. Executive Vice President, General Counsel and Corporate Secretary
Cara Miller Vice President of Corporate Communications

Latest SEC Filings

Date Type Title
Jul 10, 2024 144 Filing
Jun 26, 2024 8-K Current Report
Jun 11, 2024 144 Filing
Jun 7, 2024 144 Filing
Jun 5, 2024 8-K Current Report
May 29, 2024 8-K Current Report
May 14, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 3, 2024 10-Q Quarterly Report
May 2, 2024 8-K Current Report
Apr 19, 2024 ARS Filing